Octave Bioscience gets $30M to advance MS, neurodegenerative treatment platform
Click Here to Manage Email Alerts
A Bay Area-based precision care company has announced $30 million in funding to continue providing care for those with multiple sclerosis and other neurodegenerative diseases.
According to a release from the company, Octave Bioscience offers precision care by including blood biomarker testing, expanded imaging capabilities and clinical insights to provide a comprehensive view of the patient, including disease activity levels and progression. The current round of funding is expected to accelerate commercialization efforts to boost accessibility for Octave's unique platform.
“With our multimodal precision care solution, we are providing tools, insights and a platform that enable a personalized approach to patient care, better treatment decisions and improved outcomes,” William Hagstrom, Octave’s founder and CEO, said in the release. We have made significant progress in deploying our solution for multiple sclerosis patients.”
Among the group of investors that assisted in the funding are Novartis, Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, Intermountain Ventures, including previous investors The Blue Venture Fund, Echo Health Ventures, Section 32, Northpond Ventures, Deerfield Management, Casdin Capital and Merck Global Health Innovation Fund.